News Archive A DOUBLE FIRST FOR ROCHE AND TRIMERIS� NEW GROUND-BREAKING HIV FUSION INHIBITORS 19-Dec-01 SWATCH STUDY HIGHLIGHTS IMPORTANCE OF STRATEGIC PLANNING TO OUTWIT HIV RESISTANCE 18-Dec-01 NEW DOSAGE FOR FORTOVASE�/R SHOWS EFFICACY AND EXCELLENT SAFETY PROFILE IN HIV PATIENTS: NEW TREATMENT STRATEGY MAY REDUCE COST OF HIV THERAPY 31-Oct-01 NEW HIV DRUGS - FUSION INHIBITORS - LIKELY TO SUCCESSFULLY TACKLE RESISTANT HIV 30-Oct-01 VALCYTE RECEIVES FIRST EUROPEAN REGULATORY APPROVAL FOR TREATMENT OF AIDS-RELATED CMV RETINITIS 27-Sep-01 PREMIERE HOMOLOGATION EUROPEENNE DE VALCYTE DANS LE TRAITEMENT DE LA RETINITE A CMV LIEE AU SIDA 27-Sep-01 VALCYTE ERSTMALS IN EUROPA F�R DIE BEHANDLUNG DER AIDS-BEDINGTEN CMV-RETINITIS ZUGELASSEN 27-Sep-01 VALCYTE APROBADO POR PRIMERA VEZ EN EUROPA, PARA EL TRATAMIENTO DE LA RETINITIS CITOMEGALOV�RICA RELACIONADA CON EL SIDA 27-Sep-01 ROCHE AND BRAZILIAN MINISTRY OF HEALTH REACH AGREEMENT FOR THE SUPPLY OF HIV DRUG VIRACEPT� 03-Sep-01 ROCHE AND TRIMERIS COMPLETE HIV PHASE III TRIAL RECRUITMENT 09-Aug-01 ROCHE E TRIMERIS ASSINAM ACORDO PARA O DESENVOLVIMENTO DOS F�RMACOS DA TRIMERIS 12-Jul-99 HIV PATIENTS GIVE GREEN LIGHT TO LONG-TERM USE OF INJECTABLE T-20 11-Jul-01 LARGE VIRACEPT� (NELFINAVIR) STUDY DEMONSTRATES POTENT SUPPRESSION OF HIV AND HIGH PATIENT ADHERENCE OUT TO THREE YEARS OF THERAPY 09-Jul-01 ROCHE AND TRIMERIS BROADEN SCOPE OF HIV PARTNERSHIP 19-Jun-01 NEW DATA REINFORCES BENEFIT OF VIRACEPT IN FIRST LINE THERAPY FOR HIV INFECTION 08-Jun-01 TOP HIV SCIENTISTS MEET TO DISCUSS BETTER LONG TERM TREATMENT OUTCOMES FOR PEOPLE WITH HIV 29-May-01 FOUR STUDIES INVESTIGATE EFFECTIVENESS AND TOLERABILITY OF FORTOVASE�/R AS ONCE- DAILY PROTEASE INHIBITOR FOR HIV INFECTION 09-Apr-01 NEW INITIATIVE CREATES ACCESS TO HIV CARE AND TREATMENT IN FOUR AFRICAN COUNTRIES 28-Feb-01 NEW DATA CONFIRMS HIGHLY EFFECTIVE AND TOLERABLE ROLE OF VIRACEPT� IN FIRST LINE TREATMENT STRATEGIES OF HIV INFECTION 08-Feb-01 CALL TO ACTION: ROCHE ADVOCATES DEVELOPMENT OF HIV DRUG POTENCY GUIDELINES TO HELP PHYSICIANS MAKE OPTIMAL TREATMENT DECISIONS 23-Oct-00 ROCHE HIV PROTEASE INHIBITOR SAQUINAVIR SHOWS GREATER IN VITRO POTENCY THAN NEW DRUG LOPINAVIR 23-Oct-00 IMPORTANT PROGRESS IN TREATMENT OF HIV INFECTION TO BE REPORTED 10-Jul-00 ROCHE ANNONCE D�IMPORTANTS PROGR�S DANS LE TRAITEMENT DE L�INFECTION � VIH 10-Jul-00 WICHTIGER FORTSCHRITT BEI DER BEHANDLUNG DER HIV-INFEKTION 10-Jul-00 NUEVA INFORMACI�N SOBRE IMPORTANTES AVANCESEN EL TRATAMIENTO DE LA INFECCI�N POR EL VIH 07-Jul-00 BLOOD LEVELS OF FORTOVASE INCREASE WITH A MINI-DOSE OF RITONAVIR 15-Jun-00 INVESTIGATIONAL AIDS-RELATED ORAL DRUG VALGANCICLOVIR PROVIDES COMPARABLE RESULTS TO INTRAVENOUS CYMEVENE 03-Feb-00 VIRACEPT COMBINATION IN PREGNANT WOMEN PREVENTS HIV INFECTION IN NEWBORNS, EARLY STUDY SHOWS 02-Feb-00 SELON UNE ETUDE, LE TRAITEMENT AU VIRACEPT EN ASSOCIATION ADMINISTRE AUX FEMMES ENCEINTES EMPECHE L'INFECTION A VIH CHEZ LES NOURRISSONS 02-Feb-00 KOMBINATION MIT VIRACEPT BEI SCHWANGEREN SCH�TZT VOR HIV-INFEKTION DER NEUGEBORENEN, SO EINE FR�HE STUDIE / WEITERE STUDIE BELEUCHTET VIRACEPT ALS TEIL DER BEHANDLUNG VON KINDERN 02-Feb-00 UN ESTUDIO CLINICO COMPRUEBA QUE VIRACEPT ES EFICAZ PARA IMPEDIR LA TRANSMISION DEL VIH DE LA MADRE AL BEBE 02-Feb-00 SHIFTING TREATMENT DEMOGRAPHICS HIGHLIGHT NEED TO MANAGE LONG-TERM HIV TREATMENT OPTIONS 02-Feb-00 L'EVOLUTION DEMOGRAPHIQUE DES TRAITEMENTS HIV FAIT RESSORTIR LE BESOIN DE GERER LES DIFFERENTES OPTIONS 02-Feb-00 SICH VERSCHIEBENDE BEHANDLUNGSDEMOGRAPHIEN STELLEN NOTWENDIGKEIT IN DEN VORDERGRUND, LANGFRISTIGE HIV-BEHANDLUNGSM�GLICHKEITEN ZU SCHAFFEN 02-Feb-00 LAS L�NEAS GENERALES IAS POTENCIAN EL USO DE TERAPIAS ANTI-VIH A LARGO PLAZO PERSONALIZADAS 02-Feb-00 ROCHE AND TRIMERIS REPORT CLINICAL PROGRESS IN DEVELOPMENT OF HIV FUSION INHIBITORS 01-Feb-00 LES SOCIETES ROCHE ET TRIMERIS PRESENTENT DES PROGRES CLINIQUES DANS LE DEVELOPPEMENT D�INHIBITEURS DE FUSION VIH 01-Feb-00 ROCHE UND TRIMERIS BERICHTEN �BER KLINISCHEN FORTSCHRITT IN DER ENTWICKLUNG VON HIV FUSIONS-INHIBITOREN 01-Feb-00 ROCHE Y TRIMERIS INFORMAN DE PROGRESOS CL�NICOS EN EL DESARROLLO DE INHIBIDORES DE FUSI�N DEL VIH 01-Feb-00 NEW STUDIES SHOW REAL-LIFE ADVANTAGES OF VIRACEPT IN EFFICACY, TOLERABILITY, DRUG RESISTANCE AND CONVENIENCE 26-Oct-99 VIRACEPT TWICE-DAILY DOSING SHOWS LONG-TERM ANTI-HIV EFFECTIVENESS, STUDY SHOWS 26-Oct-99 NEW FUSION INHIBITOR T-20 COMBINATION REGIMEN REDUCES HIV LEVELS IN HEAVILY PRE-TREATED PATIENTS 25-Oct-99 UN NOUVEAU TRAITEMENT D'ASSOCIATION PAR L'INHIBITEUR DE FUSION T-20 DIMINUE LA CONCENTRATION DU VIH CHEZ LES PATIENTS QUI ONT RE�U UN TRAITEMENT INTENSIF 25-Oct-99 DIE NEUE KOMBINATIONSTHERAPIE MIT DEM FUSIONSHEMMER T-20 SENKT DIE HIV-BELASTUNG BEI UMFANGREICH VORBEHANDELTEN PATIENTEN 25-Oct-99 T-20, UN NUEVO REGIMEN DE COMBINACI�N DE INHIBIDOR DE FUSI�N REDUCE LOS NIVELES DE VIH EN PACIENTES CON TRATAMIENTOS ANTERIORES MUY ESTRICTOS 25-Oct-99 TREATMENT INCLUDING FORTOVASE SHOWS SIGNIFICANT PROMISE TO ELIMINATE HIV TRANSMISSION FROM MOTHER TO INFANT 25-Oct-99 STUDY HIGHLIGHTS POTENTIAL FOR MORE CONVENIENT ONCE-A-DAY ADMINISTRATION 25-Oct-99 FORTOVASE ONCE-A-DAY DOSING SHOWS PROMISE IN FIRST STUDY IN HIV-POSITIVE INDIVIDUALS 25-Oct-99 SIXTEEN-WEEK ANALYSIS OF HEAVILY PRE-TREATED PATIENTS RECEIVING T-20 AS A COMPONENT OF MULTI-DRUG SALVAGE THERAPY (T20-205) 27-Sep-99 NEW AIDS STUDY SUGGESTS T-20-CONTAINING REGIMENS REDUCES HIV IN HEAVILY PRE-TREATED PATIENTS 27-Sep-99 UNE NOUVELLE �TUDE SUR LE SIDA LAISSE ENTENDRE QUE LES R�GIMES TH�RAPEUTIQUES INT�GRANT LE T-20 R�DUISENT L�ACTIVIT� DU VIH CHEZ LES PATIENTS RECEVANT UN TRAITEMENT INTENSIF DE LONGUE DATE 27-Sep-99 NEUE AIDS-STUDIE SUGGERIERT, DASS T-20 ENTHALTENDE DOSIERUNGEN DIE VIRALE HIV-AKTIVIT�T BEI UMFANGREICH VORBEHANDELTEN PATIENTEN REDUZIERT 27-Sep-99 UN NUEVO ESTUDIO SUGIERE QUE EL TRATAMIENTO CON EL MEDICAMENTO T-20 REDUCE LA PRESENCIA DEL VIH EN LA SANGRE 27-Sep-99 DATA PRESENTED AT ICAAC SUPPORT FIRST-LINE USE OF VIRACEPT 27-Sep-99 LES DONN�ES PR�SENT�ES DANS LE CADRE DU CONGR�S DE L�ICAAC APPUIENT L�UTILISATION DE VIRACEPT COMME TRAITEMENT DE PREMI�RE INTENTION 27-Sep-99 DIE BEI DER ICAAC VORGELEGTEN DATEN BEKR�FTIGEN BEVORZUGTE ANWENDUNG VON VIRACEPT 27-Sep-99 LOS DATOS PRESENTADOS EN EL ICAAC APOYAN LA UTILIZACI�N DE VIRACEPT COMO TERAPIA DE PRIMERA L�NEA 27-Sep-99 BACKGROUND INFORMATION: CROSS RESISTANCE DATA PRESENTED AT ICAAC SUPPORT FIRST-LINE USE OF VIRACEPT 27-Sep-99 BACKGROUND INFORMATION: T-20 FACT SHEET 27-Sep-99 BACKGROUND INFORMATION: FORTOVASE (Saquinavir) STUDY HIGHLIGHTS POTENTIAL FOR MORE CONVENIENT ONCE-A-DAY ADMINISTRATION 26-Sep-99 STRONG PROMISE FOR ONCE-A-DAY DOSING OF FORTOVASE, STUDY SHOWS 26-Sep-99 UNE �TUDE R�V�LE L�ACTIVIT� PROMETTEUSE DE FORTOVASE � DOSE QUOTIDIENNE UNIQUE 26-Sep-99 STUDIE ZEIGT, DASS DIE EINMAL T�GLICHE DOSIERUNG MIT FORTOVASE 26-Sep-99 UN ESTUDIO MUESTRA EL POTENCIAL DEL NUEVO REGIMEN DE UNA DOSIS DIARIA DE FORTOVASE 26-Sep-99 ROCHE AND TRIMERIS SIGN AGREEMENT TO DEVELOP TRIMERIS'S COMPOUNDS 12-Jul-99 ROCHE ET TRIMERIS SIGNENT UN ACCORD PORTANT SUR LE D�VELOPPEMENT DE PRODUITS DE TRIMERIS 12-Jul-99 ROCHE UND TRIMERIS UNTERZEICHNEN VEREINBARUNG �BER DIE ENTWICKLUNG VON TRIMERIS-PR�PARATEN 12-Jul-99 ROCHE E TRIMERIS FIRMANO UN ACCORDO PER SVILUPPARE I COMPOSTI DI TRIMERIS 12-Jul-99 ROCHE Y TRIMERIS HAN FIRMADO UN ACUERDO PARA DESARROLLAR LOS COMPUESTOS DE ESTA EMPRESA 12-Jul-99 FUSION INHIBITORS:T-20 AND T-1249 BACKGROUND INFORMATION 12-Jul-99 FUSION INIHIBITORS: BACKGROUND INFORMATION 12-Jul-99 MAJOR ADVANCE IN HIV MANAGEMENT: PAN EUROPEAN HIV GENOTYPING THRUST LAUNCHED 08-May-99 PROGR�S MAJEUR DANS LE TRAITEMENT DE L'INFECTION PAR LE VIH : LANCEMENT DANS TOUTE L'EUROPE DU TYPAGE DU G�NOME DU VIH 10-May-99 WICHTIGER FORTSCHRITT IN DER HIV-BEHANDLUNG: PAN-EUROP�ISCHES HIV-GENOTYPING-VERFAHREN GESTARTET 10-May-99 BACKGROUND INFORMATION: FORTOVASE� (SAQUINAVIR): CLINICAL STUDIES HIGHLIGHT NEW FORMULATION'S POWER AND CONVENIENCE 08-May-99 BACKGROUND INFORMATION: ROCHE VIROLOGY NETWORK AND PE BIOSYSTEMS ANNOUNCE THE GREAT TRIAL 08-May-99 BACKGROUND INFORMATION: GENOTYPING 08-May-99